Loading company
Trinity Biotech plc
TRIB · Nasdaq · ·
$6.54-3.3%Sep 29 close
- 1M
- -32.4%
- 6M
- -61.3%
- 1Y
- -79.0%
- 5Y
- -98.0%
TRIB · Nasdaq · ·
$6.54-3.3%Sep 29 close
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $15.9M | $13.4M | +18.09% |
| Free Cash Flow | -$3.7M | -$4.6M | +18.28% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
The quote and the company description come from the 6-K Trinity Biotech plc filed on December 23, 2025 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Trinity Biotech plc has no earnings call transcript available.